Brielle Benyon


Patient Perceptions, Other Factors Linked to Fear of Recurrence

February 19, 2021

Fear of cancer recurrence is a common plight for people after they have completed cancer treatment, and recent research analyzed which patient characteristics were associated with higher rates of fear of recurrence.

FDA Approves Umbralisib for Relapsed/Refractory MZL and FL

February 06, 2021

The FDA approved umbralisib (Ukoniq) for the treatment of adults with relapsed/refractory marginal zone lymphoma (MZL) who had at least 1 prior anti-CD20—based regimen; and adults with relapsed/refractory follicular lymphoma (FL) who had at least 3 prior lines of systemic therapy.